LINC00515

Summary

LINC00515 (long intergenic non-protein coding RNA 515, HGNC:16019) is a long non-coding RNA gene on chromosome 21q21.3.

At a glance

• GWAS associations: 2

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:16019
Approved symbol	LINC00515
Name	long intergenic non-protein coding RNA 515
Location	21q21.3
Locus type	RNA, long non-coding
Status	Approved
Aliases	PRED21
Entrez	282566
RNAcentral	URS0000CCE13C — lncRNA, 459 nt, 1 organism(s)

Gene structure

Transcript identifiers

Ensembl transcripts: 0

RefSeq mRNA: 0 — MANE Select: None

Canonical transcript exons

None — 0 exons

Expression profiles

Top tissues by expression

0 total, by Bgee expression score (0-100, higher = more expressed):

Regulation

Is transcription factor: no

Literature-anchored findings (GeneRIF, showing 2)

• Knockdown of linc00515 leds to decreased autophagy and chemoresistance of melphalan-resistant myeloma cells. (PMID:30121664)
• LINC00515 downregulation is correlated with HGSOC development, platinum resistance and RFS (PMID:31140829)

Cross-species orthologs

0 orthologs

Protein

Protein identifiers

Canonical reviewed UniProt: None (reviewed: )

All UniProt accessions (0):

RefSeq proteins (0): (*=MANE)

Domains & families (InterPro)

Structure

Experimental structures (PDB)

0 structures.

Predicted structure (AlphaFold)

Function

Pathways and Gene Ontology

Reactome pathways

0 pathways

MSigDB gene sets: 0 (showing top):

GO Biological Process (0):

GO Molecular Function (0):

GO Cellular Component (0):

Protein interactions and networks

STRING

0 interactions, top by confidence (×1000):

IntAct

0 interactions, top by confidence:

SIGNOR signaling

0 interactions.

Disease & clinical

Clinical variants and AI predictions

ClinVar

0 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	0
Likely benign	0
Benign	0

Top pathogenic / likely-pathogenic (0)

SpliceAI

0 predictions. Top by Δscore:

AlphaMissense

0 scored. Top likely-pathogenic:

dbSNP variants (sampled 300 via entrez): RS1003279427 (21:25583010 C>A,T), RS1003639612 (21:25583330 T>C), RS1004027683 (21:25585190 C>T), RS1006537267 (21:25583732 T>A,C), RS1007458934 (21:25583448 A>G), RS1007541567 (21:25582408 A>G), RS1011449588 (21:25584759 C>T), RS1012386985 (21:25582759 A>G,T), RS1012772626 (21:25584673 C>T), RS1013363287 (21:25583124 T>C), RS1014533552 (21:25582843 T>C), RS1014564743 (21:25583024 C>T), RS1017840441 (21:25583439 A>G), RS1017871433 (21:25583749 AG>A), RS1018871287 (21:25583870 T>C)

Disease associations

OMIM: gene `` | disease phenotypes:

GenCC curated gene-disease

Mondo (0):

Orphanet (0):

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

2 associations (top):

Study	Trait	p-value
GCST007600_4	Alzheimer’s disease	3.000000e-07
GCST007600_7	Alzheimer’s disease	4.000000e-07

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

CTD chemical–gene interactions

16 total (human), top 16 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Valproic Acid	affects cotreatment, decreases expression, decreases methylation	7
trichostatin A	affects cotreatment, decreases expression	2
entinostat	decreases expression, affects cotreatment	2
Panobinostat	affects cotreatment, decreases expression	2
Phenylmercuric Acetate	affects cotreatment, decreases expression	2
methylmercuric chloride	decreases expression	1
bisphenol A	increases expression	1
butyraldehyde	decreases expression	1
pentanal	decreases expression	1
4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide	decreases expression, affects cotreatment	1
dorsomorphin	affects cotreatment, decreases expression	1
Benzo(a)pyrene	decreases methylation	1
Cisplatin	increases expression	1
Estradiol	increases expression	1
Malathion	increases expression	1
Rotenone	decreases expression	1

Clinical trials (associated diseases)

0 trials via MONDO — disease-level, not drug-specific.